GSK'963 is primarily utilized in biomedical research as a potent and selective inhibitor of RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1). Its application is significant in studying necroptosis, a form of programmed cell death, and its role in various inflammatory and degenerative diseases. Researchers employ GSK'963 to explore potential therapeutic strategies for conditions such as Alzheimer's disease, multiple sclerosis, and ischemic injury, where RIPK1-mediated pathways are implicated. By inhibiting RIPK1, it helps in understanding the molecular mechanisms underlying these diseases and aids in the development of targeted treatments. Additionally, GSK'963 is used in preclinical studies to assess its efficacy and safety as a potential drug candidate for modulating cell death pathways.